In the phase 2 ETOP ADEPPT trial, researchers sought to determine whether adagrasib, a KRAS G12C inhibitor, was effective in older patients and those with ECOG PS 2.

ART can safely replace ALND, with no axillary recurrences, and fewer cases of lymphedema in patients with breast cancer.

Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...

Nutritional decline was most pronounced early in therapy. Weight nadirs most commonly occurred on days 8 (21.6%), 22 (22.9%), and 35 (21.6%), while TSFT nadirs clustered on day 8 (31.6%) and day 15 ...